Fresh analysis indicates that individuals who discontinue blockbuster slimming jabs like Wegovy and Mounjaro may regain lost weight much more quickly than those who stop traditional lifestyle regimens.
Research printed in a leading medical journal shows that while overweight individuals often shed a large proportion of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these medications need to be aware of the potential of fast weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight within about a year and a half.
Analyzing Treatments
The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods.
Scientists emphasize that people who lose weight through diet and exercise typically see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors suggest the way of the injections explains the amplified rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels far above than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in appetite is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Health authorities advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals argue that, due to the high risk of weight regain, the therapy is often life-long.
This perspective is supported by pharmaceutical companies, who note that the results "underscore the persistent character of obesity," akin to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the jabs describe a sudden resurgence of cravings.
"I experienced something that goes on and I was suddenly starving," described a patient.
This difficulty is exacerbated if patients have not established lasting lifestyle or habit modifications during treatment.
Growing Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on combined lifestyle management.
